Approximately 20% of breast cancer patients exhibit triple‐negative breast cancer (TNBC) characterized by a lack of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (Her2) expression.2, 3, 4. This evidence concerns the gene ESR1 and breast carcinoma.